The global single-use bioreactors market size was valued at USD 2,730.3 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 17.6% from 2022 to 2030. Single-use systems are emerging as an important technology for pharmaceutical and mammalian cell culture applications. They are particularly well suited for biopharmaceutical production, where prevailing market trends call for quick, easy, and flexible deployment. In addition, with comprehensive qualification and validation procedures, the use of single-use bioreactors lowers the possibility of cross-contamination and improves process safety in highly potent biopharmaceutical compounds. These factors are anticipated to drive the market for single-use bioreactors.
The usage of SUBs is growing at an annual rate of 11%, according to the 16th Annual Report of Biomanufacturing. The range of stainless-steel bioreactors and associated high capital costs has become a challenge due to changing demand for biopharmaceuticals. SUBs' versatility to meet the rising demand for biopharmaceuticals has enabled them to successfully address the issues related to traditional bioreactors. Flexibility offered by single-use bioreactors is one of the main encouraging factors of investing in technology that further drives market growth.
Additionally, it is projected that in the upcoming years, the use of disposable bioreactors will pick up steam due to the increased demand for biopharmaceuticals across the globe. Small-scale, bench-top SUBs reduce the requirement for assembling, cleaning, and autoclaving, which leads to quicker turnaround times. The advantages offered by SUBs motivate their use for the manufacturing of biopharmaceuticals.
SUBs also have the potential to be less expensive than traditional bioreactors. They typically have lower implementation costs than traditional stainless-steel bioreactor systems. Therefore, the cost-saving benefits of these items in terms of construction, operation, and cleaning can be primarily attributable to their adoption. Cost, desired operating volume, reaction size, temperature control, and capacity are deciding factors when choosing single-use bioreactors.
Increasing investment flow by key players in the production of advanced & effective equipment is likely to support market growth throughout the projected timeframe. For instance, in March 2022, Dundee-based Cellexus International introduced single-use airlift bioreactor that helps scientists to grow fragile cell cultures for their study more quickly and affordable. Instead of employing harsher mixing methods, the CellMaker single-use airlift bioreactors produce bubbles that percolate through the mixture, generating a gentle mixing action for even the most fragile cell cultures. Such initiatives by companies are likely to supplement the market growth in the coming years.
The single use bioreactor systems segment captured the largest market share of over 80.0% in 2021. Single-use bioreactor systems are widely used in biopharmaceutical manufacturing processes that require high product yield. The versatility, cost-effectiveness, and high mass production capability of Single-use bioreactors would increase demand for the products leading to rapid market growth.
Furthermore, the rising demand for quick development, greater production of new bio-therapeutics including vaccines, antibodies, enzymes, and hormones, and an increase in the product quantities that can be produced in these bioreactors, contributing to the market's ongoing expansion. In addition, the increased focus of prominent manufacturers on offering small-scale bioreactors will fuel segment expansion over the next years
The stirred tank bioreactors segment dominated the market and accounted for the largest revenue share of 81.4% in 2021. The benefits offered by these bioreactors includes good oxygen transfer and fluid mixing ability, easy scale-up, low operating costs, compliance with cGMP requirements and alternative impellers have led to the highest penetration of stirred tank bioreactors in the market.
Additionally, the availability of wave-induced bioreactors will increase in the coming years, boosting market growth. In addition, for the past ten years, Wave Biotech AG has sold the original wave SUBs BIOSTAT RM. In 2019, the business unveiled the second version, BIOSTAT RM II, which has more sophisticated features & enhanced control of temperature and driving system. The demand for Wave-induced SUBs is anticipated to increase due to these manufacturing developments over the forecasted period. Therefore, such type of advancements by the manufacturers will drive segmental growth in the forecast period.
The mammalian cells segment dominated the market and accounted for the largest revenue share of 81.3% in 2021. This can be attributed to the significant penetration of this cell type in the creation of biopharmaceutical therapies and the commercial success of recombinant proteins made from mammalian cells. As per BioProcess International, 85% of biopharmaceutical candidates in clinical development are made using mammalian cell cultures.
Yeasts are dependable eukaryotic hosts for the synthesis of heterologous proteins and offer special benefits in the generation of therapeutic recombinants. The increasing attention given by numerous research organizations and scientists to the use of yeast cells in clinical or therapeutic settings will hasten market expansion during the projected timeframe. For instance, research published by NCBI in June 2021 examined cutting-edge techniques and approaches for synthesizing heterologous medicinal proteins from yeast genes
The vaccines segment dominated the market and accounted for the largest revenue share of 27.5% in 2021. This is majorly attributed to the COVID-19 outbreak, which has resulted in an urgent need for the development of a virus vaccine. According to Bioplan Associates, the use of single-use systems in the commercial manufacturing of vaccines is anticipated to rise sharply. Many biopharmaceutical companies are actively engaged in the quick development of COVID-19 vaccines in response to the COVID-19 pandemic.
Additionally, the growing field of cell and gene therapies is anticipated to accelerate the uptake of SUBs in this market. For instance, in January 2021, Sartorius and RoosterBio, Inc. teamed up to improve the production capabilities for gene and cell therapies. The partnership aims to increase the manufacturing of regenerative medicine. Such an ongoing and continuous increase in the adoption of single-use systems is anticipated to drive market growth.
In 2021, the research and development (R&D)/process development segment accounted for the largest revenue share at 77.7%. Single-use bioreactor utilization in process development is a driving force behind market expansion. For instance, according to an article published in 2020 by American Pharmaceutical Review, the industry has employed about 71.2% of single-use bioreactors for process development.
Furthermore, every component of the bioprocessing sector uses single-use systems. According to the American Pharmaceutical Review, single-use system devices are used for clinical or process development in about 85% of operations. This demonstrates the predominance of single-use bioreactors in both clinical manufacturing and R&D.
The bioproduction sector is expected to see significant use of SUBs in the near future due to the numerous benefits they provide. The widespread use of disposable reactors, from the lab to the industrial, has increased as a result of significant developments in bioreactor designs, sensor systems, and stirring motors.
The lab-scale production segment captured the largest revenue share of 35.9% in 2021. In the biopharmaceutical business, disposable bioreactors are frequently employed in preclinical and clinical research. It is anticipated that growing single-use technology acceptance would have a substantial impact on segment growth in cell-based therapy research and vaccine production.
Throughout the projected period, it is anticipated that the large-scale production category would experience significant expansion. This is due to the quickly expanding market demand for the commercial production of biopharmaceutical goods and the growth of manufacturing capacity to accommodate these demands. For instance, Wuxi Biologics introduced a 36,000L biomanufacturing line in February 2021, employing nine 4,000L single-use bioreactors.
The CMOs and CROs segment accounted for a significant revenue share of 50.0% in 2021. The demand for supply production capacity as well as quick awareness campaign change-overs is more among CMOs. As a result, they use a broader range of single-use components and systems. With the increasing trend of outsourcing, CROs & CMOs are more likely to adopt SUBs.
On the other hand, pharmaceutical and biopharmaceutical companies are estimated to witness significant growth. According to estimates, 66% of biopharmaceutical firms use disposable bioreactors in their daily operations. The market expansion was further reinforced by strategic alliances between product producers and biopharmaceutical firms. For instance, BioCentriq and Pall Corporation worked together in July 2021 to clinically manufacture Zolgensma, an FDA-approved gene therapy, utilising an iCELLis fixed bed bioreactor.
North America dominated the regional market with a share of 33.6% in 2021. This is explained by the fact that the region has well-established biopharmaceutical companies and key operating players. Additionally, the region's increased production capacity has added to the market expansion. For instance, Thermo Fisher Scientific stated in September 2021 that it would build a new manufacturing facility specifically for single-use bioprocessing products.
A significant element influencing the growth of the single-use bioreactors market in the U.S. is the changing environment for manufacturing and bioprocessing. In cooperation with the Biomedical Advanced Research and Development Authority, Cytiva launched a new production facility for Xcellerex XDR single-use bioreactors in the United States in December 2020. It is a component of the company's USD 500 million worldwide manufacturing expansion plan.
Asia Pacific is estimated to witness the fastest CAGR throughout the forecast period. According to estimates, Asian businesses, including both domestic contenders and global behemoths, are building approximately half of all new bioprocessing facilities worldwide. In the near future, this is anticipated to significantly fuel market expansion in the Asia Pacific region.
Key players in this market are implementing various strategies including partnerships through mergers and acquisitions, geographical expansion, and strategic collaborations to expand their market presence. For instance, in June 2022, Exothera SA has partnered with LogicBio Therapeutics and Polyplus-transfection SA to produce a highly scalable AAV manufacturing platform. The Allegro stirred tank single-use bioreactors manufactured by Pall Corporation have been selected for this project. Some of the key players in the global single-use bioreactors market include:
Sartorius Stedim Biotech
Thermo Fisher Scientific
Celltainer Biotech BV
PBS Biotech Inc.
Able Corporation & Biott Corporation
G&G Technologies Inc.
Solida Biotech GmbH
Satake Chemical Equipment Mfg., Ltd.
Stobbe Pharma GmbH
Market size value in 2022
USD 3,304.1 million
Revenue forecast in 2030
USD 12,062.5 million
CAGR of 17.6% from 2022 to 2030
Base year for estimation
2018 - 2020
2022 - 2030
Revenue in USD million and CAGR from 2022 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, type, type of cell, molecule type, application, end-use, usage type, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Mexico; South Africa; Saudi Arabia
Key companies profiled
Sartorius Stedim Biotech; Thermo Fisher Scientific; Danaher; Merck KgaA; Celltainer Biotech BV; Getinge AB; Eppendorf AG; Cellexus; PBS Biotech Inc.; Distek Inc.; ABEC; Able Corporation & Biott Corporation; G&G Technologies Inc.; Solida Biotech GmbH; Satake Chemical Equipment Mfg., Ltd.; Stobbe Pharma GmbH; bbi-biotech GmbH
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global single-use bioreactors market report on the basis of product, type, type of cell, molecule type, application, end-use, usage type, and region:
Product Scope Outlook (Revenue, USD Million, 2018 - 2030)
Single-use bioreactor systems
Up to 10L
Single-use media bags
Single-use Filtration Assemblies
Type Outlook (Revenue, USD Million, 2018 - 2030)
Type of Cell Outlook (Revenue, USD Million, 2018 - 2030)
Molecule Type Outlook (Revenue, USD Million, 2018 - 2030)
Gene Modified Cells
Application Outlook (Revenue, USD Million, 2018 - 2030)
Research And Development (R&D) or Process Development
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biopharmaceutical Companies
CROs & CMOs
Academic & Research Institutes
Usage Type Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global single-use bioreactors market size was estimated at USD 2,730.3 million in 2021 and is expected to reach USD 33,04.1 million in 2022.
b. The global single-use bioreactors market is expected to grow at a compound annual growth rate of 17.6% from 2022 to 2030 to reach USD 12,062.5 million by 2030.
b. Single-use bioreactor systems dominated the single-use bioreactors market with a share of 82.4% in 2021. This is attributed to the various commercial advantages offered by their systems coupled with increasing adoption by end-users in the market.
b. Some key players operating in the single-use bioreactors market include Thermo Fisher Scientific, Sartorius Stedim Biotech, Danaher, Merck KgaA, Celltainer Biotech BV, Getinge AB, Eppendorf AG, Cellexus, PBS Biotech Inc., and Distek Inc.
b. Key factors that are driving the single-use bioreactors market growth include increasing adoption of SUBs among small companies and startups, reduction in automation complexity, reduction in energy and water consumption, rising research in the biopharmaceutical market, and technological advancements in SUBs.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."